FIELD: biotechnology.
SUBSTANCE: invention refers to anti-tumor peptide vaccines, and can be used in medicine for treating or preventing cancer. Vaccine contains a modified peptide based on peptide WT1187 or WT1126 with replacement of one amino acid residue in amino acid sequence of the specified peptide, without affecting amino acid residues in positions 4–8 from its N-terminus.
EFFECT: invention is effective against malignant tumors accompanied by increased expression of WT1 gene in HLA-A*0201 positive individuals.
23 cl, 32 dwg, 25 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINATIVE TUMOR VACCINE COMPOSITION | 2008 |
|
RU2682726C2 |
| HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| ANTIBODY AGAINST MALIGNANT CELL, ANTI-CANCER DRUG AND METHOD FOR TESTING MALIGNANT NEOPLASM | 2015 |
|
RU2753512C2 |
